Collignon-Brach J
Université de Liege, Belgium.
Surv Ophthalmol. 1994 May;38 Suppl:S149-55. doi: 10.1016/0039-6257(94)90059-0.
In a prospective, randomized study, nineteen patients with ocular hypertension (n = 14) or chronic open-angle glaucoma (n = 5) were treated with either betaxolol 0.5% or timolol 0.5% in both eyes twice daily. Visual field sensitivity and intraocular pressure were assessed with the Octopus perimeter (program G1) and applanation tonometry, respectively, at 3, 6, 12, 24, 36, and 48 months during treatment. Four of the nineteen patients (two timolol-treated and two betaxolol-treated) were lost to follow-up after the 36-month examination. Whereas both drugs reduced the intraocular pressure, the decrease in the timolol-treated group was statistically more pronounced than in the betaxolol-treated group at month 3, 6, and 48 (p < 0.03). In both treatment groups, the visual field mean sensitivity (MS) index decreased slightly during the first six months of treatment, but remained so only in the timolol-treated group at all subsequent examinations. In the betaxolol-treated group, there was a statistically significant increase in MS at the 12, 24, 36, and 48 month visits (p < 0.01). These findings suggest that factors other than IOP alone may determine visual field outcome.
在一项前瞻性随机研究中,19例高眼压症患者(n = 14)或慢性开角型青光眼患者(n = 5)双眼每日两次使用0.5%倍他洛尔或0.5%噻吗洛尔进行治疗。在治疗期间的3、6、12、24、36和48个月,分别使用Octopus视野计(程序G1)和压平眼压计评估视野敏感度和眼压。19例患者中有4例(2例接受噻吗洛尔治疗,2例接受倍他洛尔治疗)在36个月检查后失访。两种药物均能降低眼压,但在第3、6和48个月时,噻吗洛尔治疗组的眼压下降在统计学上比倍他洛尔治疗组更显著(p < 0.03)。在两个治疗组中,视野平均敏感度(MS)指数在治疗的前六个月略有下降,但仅在噻吗洛尔治疗组的所有后续检查中保持下降。在倍他洛尔治疗组中,在第12、24、36和48个月随访时MS有统计学显著增加(p < 0.01)。这些发现表明,可能是眼压以外的其他因素决定了视野结果。